non Hodgkin

Latest articles

15m
San Francisco Chronicle
FDA approves second gene-altering treatment for cancercancer. The new therapy, Yescarta, made by Kite Pharma, was approved for adult
San Francisco Chronicle / Posted 15 minutes ago
cancer. The new therapy, Yescarta, made by Kite Pharma, was approved for adults with aggressive forms of a blood cancer, non-Hodgkin lymphoma, who have undergone two regimens of chemotherapy that failed. The treatment, considered a form of gene... Read more
103 related articles
1h
Fortune
The FDA Just Approved a 2nd Revolutionary Gene Therapy. A 3rd Is Probably on the WayKite Pharma for just under $12 billion at the end of the summer) is approved fo
Fortune / Posted an hour ago
Kite Pharma for just under $12 billion at the end of the summer) is approved for certain types of the blood cancer non-Hodgkin lymphoma. Novartis’ Kymriah was approved for a form of aggressive leukemia. But taking out and re-configuring... Read more
103 related articles
1h
Business Insider
A revolutionary treatment could help more than 10,000 people living with largely untreatable canceris gaining momentum. On Wednesday, the FDA approved Yescarta, which treats a t
Business Insider / Posted an hour ago
is gaining momentum. On Wednesday, the FDA approved Yescarta, which treats a type of blood cancer called aggressive B-cell non-Hodgkin lymphoma. The highly personalized cancer treatment is a type of CAR T-cell therapy (CAR is short for chimeric... Read more
103 related articles
2h
Stamford Advocate
A revolutionary treatment could help more than 10,000 people living with largely untreatable cancer (GILD)is gaining momentum. On Wednesday, the FDA approved Yescarta, which treats a t
Stamford Advocate / Posted 2 hours ago
is gaining momentum. On Wednesday, the FDA approved Yescarta, which treats a type of blood cancer called aggressive B-cell non-Hodgkin lymphoma. But Wednesday's approval could up being a much bigger deal, in large part because the drug is approved... Read more
103 related articles
2h
Connecticut Post
A revolutionary treatment could help more than 10,000 people living with largely untreatable cancer (GILD)is gaining momentum. On Wednesday, the FDA approved Yescarta, which treats a t
Connecticut Post / Posted 2 hours ago
is gaining momentum. On Wednesday, the FDA approved Yescarta, which treats a type of blood cancer called aggressive B-cell non-Hodgkin lymphoma. But Wednesday's approval could up being a much bigger deal, in large part because the drug is approved... Read more
103 related articles
4h
KECI Missoula
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomascontent (CNN) - The U.S. Food and Drug Administration has approved a second ge
KECI Missoula / Posted 4 hours ago
content (CNN) - The U.S. Food and Drug Administration has approved a second gene therapy for cancer, the first to target non-Hodgkin lymphomas. The therapy, Yescarta (axicabtagene ciloleucel), is intended for adult patients with certain types of... Read more
103 related articles
4h
WCYB 5 Tri-Cities
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomascontent (CNN) - The U.S. Food and Drug Administration has approved a second ge
WCYB 5 Tri-Cities / Posted 4 hours ago
content (CNN) - The U.S. Food and Drug Administration has approved a second gene therapy for cancer, the first to target non-Hodgkin lymphomas. The therapy, Yescarta (axicabtagene ciloleucel), is intended for adult patients with certain types of... Read more
103 related articles
4h
KRDO Colorado Springs
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomascontent (CNN) - The U.S. Food and Drug Administration has approved a second ge
KRDO Colorado Springs / Posted 4 hours ago
content (CNN) - The U.S. Food and Drug Administration has approved a second gene therapy for cancer, the first to target non-Hodgkin lymphomas. The therapy, Yescarta (axicabtagene ciloleucel), is intended for adult patients with certain types of... Read more
103 related articles
4h
ABC 7 El Paso
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomascontent (CNN) - The U.S. Food and Drug Administration has approved a second ge
ABC 7 El Paso / Posted 4 hours ago
content (CNN) - The U.S. Food and Drug Administration has approved a second gene therapy for cancer, the first to target non-Hodgkin lymphomas. The therapy, Yescarta (axicabtagene ciloleucel), is intended for adult patients with certain types of... Read more
103 related articles
5h
News 8000
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomascontent (CNN) - The U.S. Food and Drug Administration has approved a second ge
News 8000 / Posted 5 hours ago
content (CNN) - The U.S. Food and Drug Administration has approved a second gene therapy for cancer, the first to target non-Hodgkin lymphomas. The therapy, Yescarta (axicabtagene ciloleucel), is intended for adult patients with certain types of... Read more
103 related articles
5h
Daily Mail
Benedict Cumberbatch takes time out to raise money for charity eventby a family friend, actress Siobhan Hewlett, whose soap star mother, Therese Mc
Daily Mail / Posted 5 hours ago
by a family friend, actress Siobhan Hewlett, whose soap star mother, Therese McMurray was diagnosed with a rare type of non-Hodgkin lymphoma back in 2010 and is receiving treatment at The Royal Marsden. Siobhan said: 'Without The Royal Marsden... Read more
6h
FOX 2 News St. Louis
FDA approves 2nd gene therapy targeting non-Hodgkin lymphomasliquid from a tube. The US Food and Drug Administration has approved a second
FOX 2 News St. Louis / Posted 6 hours ago
liquid from a tube. The US Food and Drug Administration has approved a second gene therapy for cancer, the first to target non-Hodgkin lymphomas. The therapy, Yescarta (axicabtagene ciloleucel), is intended for adult patients with certain types of... Read more
103 related articles
6h
The Hindu
U.S. approves second gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
The Hindu / Posted 6 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
7h
Daily Mail
US regulators approve 2nd gene therapy for blood canceraggressive form of blood cancer The new therapy, called Yescarta uses the same
Daily Mail / Posted 7 hours ago
aggressive form of blood cancer The new therapy, called Yescarta uses the same CAR-T technology as the first to fight an non-Hodgkins lymphoma The therapy uses a patient's own immune system cells and reprograms them to find and fight aggressive... Read more
103 related articles
7h
CBS News
Gene therapy for blood cancer wins FDA approvalor fast-growing, large B-cell lymphoma. The most common one accounts for about
CBS News / Posted 7 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
7h
Chicago Tribune
University of Chicago to offer newly approved gene therapy for adults with cancerThe treatment uses a patient’s own modified cells to fight the most common form
Chicago Tribune / Posted 7 hours ago
The treatment uses a patient’s own modified cells to fight the most common form of non-Hodgkin lymphoma, which is a blood cancer. The treatment is intended for adults who haven’t responded to more traditional therapies or who relapsed after those... Read more
103 related articles
7h
Mashable
Game-changing gene therapy to treat blood cancer approved by the FDAtargets a different form of cancer, that number is just above one-third. Gilea
Mashable / Posted 7 hours ago
targets a different form of cancer, that number is just above one-third. Gilead’s treatment is for the most common form of non-Hodgkin lymphoma, a particularly aggressive cancer called diffuse large B cell lymphoma, or DLBCL, which affects about... Read more
103 related articles
8h
WSFA 12 Montgomery
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
WSFA 12 Montgomery / Posted 8 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
8h
TribLIVE
FDA approves gene therapy to treat adult lymphomaFood and Drug Administration has approved a treatment that genetically alters p
TribLIVE / Posted 8 hours ago
Food and Drug Administration has approved a treatment that genetically alters patients' cells to attack cancer in fighting non-Hodgkin lymphoma. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead... Read more
103 related articles
10h
Reuters
FDA approves Gilead cancer gene therapy; price set at $373,000approved the gene therapy, to be sold under the name Yescarta, to treat adults
Reuters / Posted 10 hours ago
approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments. Gilead, which recently acquired Kite Pharma, said the... Read more
103 related articles
10h
Channel NewsAsia
US FDA approves Gilead cancer gene therapy; price set at US$373,000approved the gene therapy, to be sold under the name Yescarta, to treat adults
Channel NewsAsia / Posted 10 hours ago
approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments. Gilead, which recently acquired Kite Pharma, said the... Read more
103 related articles
11h
CTV News
U.S. regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
CTV News / Posted 11 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
11h
Reuters
U.S. FDA approves Gilead cancer gene therapy; price set at $373,000approved the gene therapy, to be sold under the name Yescarta, to treat adults
Reuters / Posted 11 hours ago
approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments. Gilead, which recently acquired Kite Pharma, said the... Read more
103 related articles
12h
The Jewish Press
Kite Pharma, Launched by Israeli Scientists, Gets FDA Approval for Lymphoma Treatment | 29 Tishri 5778 – October 19, 2017antigen receptor (CAR) T cell therapy, is the second gene therapy approved by t
The Jewish Press / Posted 12 hours ago
antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL). The new drug’s maker, Kite Pharma, an industry leader in the emerging field of cell therapy... Read more
103 related articles
14h
Newswise
Fred Hutch statement on FDA’s CAR T-cell decisionthe chimeric antigen receptor immunotherapy axicabtagene ciloleucel (Yescarta)
Newswise / Posted 14 hours ago
the chimeric antigen receptor immunotherapy axicabtagene ciloleucel (Yescarta) as a treatment for adults with aggressive non-Hodgkin lymphoma, or NHL, who have failed to respond to standard treatments. The American Cancer Society estimates that... Read more
103 related articles
15h
WECT 6 Wilmington
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
WECT 6 Wilmington / Posted 15 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
16h
Stamford Advocate
A cancer treatment that's part of 'a big new field of medicine' just got approved (GILD)revolutionary cancer treatment. The treatment, called Yescarta, treats a type
Stamford Advocate / Posted 16 hours ago
revolutionary cancer treatment. The treatment, called Yescarta, treats a type of blood cancer called aggressive B-cell non-Hodgkin lymphoma. It's a type of cancer immunotherapy, which harnesses the body's immune system to take on cancer cells.... Read more
103 related articles
16h
Connecticut Post
A cancer treatment that's part of 'a big new field of medicine' just got approved (GILD)revolutionary cancer treatment. The treatment, called Yescarta, treats a type
Connecticut Post / Posted 16 hours ago
revolutionary cancer treatment. The treatment, called Yescarta, treats a type of blood cancer called aggressive B-cell non-Hodgkin lymphoma. It's a type of cancer immunotherapy, which harnesses the body's immune system to take on cancer cells.... Read more
103 related articles
17h
KWWL Iowa
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
KWWL Iowa / Posted 17 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
17h
WBOC Salisbury
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
WBOC Salisbury / Posted 17 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
17h
WFMJ Youngstown
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
WFMJ Youngstown / Posted 17 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
17h
WLOX-TV Biloxi
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
WLOX-TV Biloxi / Posted 17 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
17h
WIS News 10 Columbia
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
WIS News 10 Columbia / Posted 17 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
17h
ABC Montana
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
ABC Montana / Posted 17 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
17h
Jefferson City News Tribune
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
Jefferson City News Tribune / Posted 17 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
18h
Lake Placid News
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
Lake Placid News / Posted 18 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
18h
FOX Business
FDA approves Gilead cancer gene therapy; price set at $373,000approved the gene therapy, to be sold under the name Yescarta, to treat adults
FOX Business / Posted 18 hours ago
approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments. Gilead, which recently acquired Kite Pharma, said the... Read more
103 related articles
18h
FOX Business
FDA approves Gilead cancer gene therapy; price set at $373,000approved the gene therapy, to be sold under the name Yescarta, to treat adults
FOX Business / Posted 18 hours ago
approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments. Gilead, which recently acquired Kite Pharma, said the... Read more
103 related articles
19h
Business Insider
A cancer treatment that's part of 'a big new field of medicine' just got approvedrevolutionary cancer treatment. The treatment, called Yescarta, treats a type
Business Insider / Posted 19 hours ago
revolutionary cancer treatment. The treatment, called Yescarta, treats a type of blood cancer called aggressive B-cell non-Hodgkin lymphoma. It's a type of cancer immunotherapy, which harnesses the body's immune system to take on cancer cells.... Read more
103 related articles
19h
WAVE 3 Louisville
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
WAVE 3 Louisville / Posted 19 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
19h
Your Hometown Lima Stations
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
Your Hometown Lima Stations / Posted 19 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
20h
FOX 8 New Orleans
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
FOX 8 New Orleans / Posted 20 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
20h
NBC 2 Fort Myers
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
NBC 2 Fort Myers / Posted 20 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
20h
KHQ Spokane
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
KHQ Spokane / Posted 20 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
20h
KFDA-TV Amarillo
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
KFDA-TV Amarillo / Posted 20 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
20h
KCBD-TV Lubbock
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
KCBD-TV Lubbock / Posted 20 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
20h
WQOW Eau Claire
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
WQOW Eau Claire / Posted 20 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
21h
Fortune
Gilead's New Cancer Gene Therapy Has Been Approved by the FDAapproved the gene therapy, to be sold under the name Yescarta, to treat adults
Fortune / Posted 21 hours ago
approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments. Gilead, which recently acquired Kite Pharma, said the... Read more
103 related articles
21h
ABC 7 Gulfshore News
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
ABC 7 Gulfshore News / Posted 21 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
21h
14 WFIE Evansville
US regulators approve 2nd gene therapy for blood canceror fast-growing, large B-cell lymphoma. The most common one accounts for about
14 WFIE Evansville / Posted 21 hours ago
or fast-growing, large B-cell lymphoma. The most common one accounts for about a third of the estimated 72,000 new cases of non-Hodgkin lymphoma diagnosed each year. Yescarta, also known as axicabtagene ciloleucel, was approved for patients who... Read more
103 related articles
More

In this news